Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

Inclusion Criteria

• Male or female adults ≥ 18 years of age.
• Diagnosis of chronic plaque-type scalp psoriasis.
• IGA of mild or greater (scalp only) determined at screening
• Scalp surface area of 30% or greater determined at screening
• Able to give written informed consent prior to performance of any study related procedures.
• Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom, diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
• Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination.

Exclusion Criteria

• <30% scalp surface area
• Scalp Investigator global assessment (IGA) clear or almost clear at time of screening
• Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.
• Pregnant or breast feeding, or considering becoming pregnant during the study.
• Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
• Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine).
• Use of ustekinumab and/or anti-IL-17 (interleukin 17) biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose.
• Patient used other topical therapies to treat within 2 weeks of the Baseline Visit (not including permitted topical therapy for face, groin and axilla).
• Patient received ultraviolet B, UVB phototherapy within 2 weeks of Baseline.
• Patient received psoralen and Ultraviolet A, PUVA phototherapy within 4 weeks of Baseline.
• Patient has a known hypersensitivity to the excipients of Topicort Spray® as stated in the label.